This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2011 Jan;8(1):3.

doi: 10.1038/nrgastro.2010.205.

IBD: Visilizumab not useful for intravenous steroid-refractory ulcerative colitis

PMID: 21265059
DOI: 10.1038/nrgastro.2010.205

Comment

IBD: Visilizumab not useful for intravenous steroid-refractory ulcerative colitis

Natalie J Wood. Nat Rev Gastroenterol Hepatol. 2011 Jan.

. 2011 Jan;8(1):3.

doi: 10.1038/nrgastro.2010.205.

Author

PMID: 21265059
DOI: 10.1038/nrgastro.2010.205

No abstract available

PubMed Disclaimer

Comment on

Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis.
Sandborn WJ, Colombel JF, Frankel M, Hommes D, Lowder JN, Mayer L, Plevy S, Stokkers P, Travis S, Van Assche G, Baumgart DC, Targan SR. Sandborn WJ, et al. Gut. 2010 Nov;59(11):1485-92. doi: 10.1136/gut.2009.205443. Gut. 2010. PMID: 20947884 Clinical Trial.

References

1. Gut. 2010 Nov;59(11):1485-92 - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.